SCHEMBL6493089

SCHEMBL6493089

CCCCS(=O)(=O)NC(=O)c1ccc2nc(C)n(Cc3ccc(NC(=O)OC(C)(C)C)cc3Cl)c2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.51
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 2/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
AGTR1 P30556 7/20 0.36
AGTR2 P50052 7/20 0.36
ACSS2 Q9NR19 1/20 0.36
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PTGES O14684 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
NPC1 O15118 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493044 0.98 PPARG (0.54) PPARGMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL6494525 0.92 PPARG (0.53) PPARGMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL6492824 0.90 PPARG (0.51) PPARGMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL6491134 0.89 PPARG (0.56) PPARGMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL6502373 0.88 ALDH1A1 (0.40) PPARGMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL6502383 0.88 ALDH1A1 (0.40) PPARGMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL6494837 0.88 PPARG (0.55) PPARGMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL6491902 0.87 PPARG (0.54) PPARGMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL6492586 0.86 PPARG (0.44) PPARGACSS2
SCHEMBL6504715 0.85 PPARG (0.60) PPARGMAPTALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US claimed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP claimed
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A PPARG 858/4885MAPT 4144/4885ALDH1A1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.